Clinical trials in St Germain En Laye – page 77

3 345 clinical trials in St Germain En Laye, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

St Germain En Laye at a glance

3 345

clinical trials

Research sites1

Quick filters

3 345 trials in St Germain En Laye

Open in trial search

Appendicitis+1

Recruiting

Study on Post-Surgery Antibiotic Use in Patients with Complicated Acute Appendicitis: Evaluating Metronidazole, Ceftriaxone, and Ofloxacin Hydrochloride

Registered drugNo placebo

Study on Post-Surgery Antibiotic Use in Patients with Complicated Acute Appendicitis: Evaluating Metronidazole, Ceftriaxone, and Ofloxacin Hydrochloride

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ceftriaxone Sodium
Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Contact Research Centre

Hepatocellular carcinoma

Recruiting

Study on Atezolizumab and Bevacizumab for Patients with Small Hepatocellular Carcinoma Undergoing Radiofrequency Ablation

Registered drugNo placebo

Study on Atezolizumab and Bevacizumab for Patients with Small Hepatocellular Carcinoma Undergoing Radiofrequency Ablation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Centre Hospitalier Universitaire De Montpellier

Contact Research Centre

Cryoglobulinaemia

Recruiting

Study of Belimumab versus Placebo for Treatment of Non-infectious Active Cryoglobulinemia Vasculitis in Adult Patients

Registered drug

Study of Belimumab versus Placebo for Treatment of Non-infectious Active Cryoglobulinemia Vasculitis in Adult Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Belimumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:Institut Gustave Roussy

Contact Research Centre

Systemic scleroderma

Recruiting

Study on the Safety of Allogeneic Adipose-Derived Mesenchymal Stromal Cells for Patients with Severe Systemic Sclerosis

Investigational

Study on the Safety of Allogeneic Adipose-Derived Mesenchymal Stromal Cells for Patients with Severe Systemic Sclerosis

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Adenocarcinoma gastric

Recruiting

Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

Registered drugNo placebo

Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:EXL01
Sponsor:Gercor

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Registered drugNo placebo

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Registered drugNo placebo

France

Participants:0–17 years
Substances:Ponatinib
Sponsor:Incyte Biosciences International S.a.r.l.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study Comparing Standard and Adjusted Doses of Alectinib for Patients with ALK Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Standard and Adjusted Doses of Alectinib for Patients with ALK Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alectinib
Sponsor:Universitair Medisch Centrum Groningen

Contact Research Centre

Herpes simplex reactivation

Recruiting

Study on Acyclovir for Patients with Herpes Simplex Virus Reactivation in the Throat on Mechanical Ventilation with One or No Organ Failure

Registered drug

Study on Acyclovir for Patients with Herpes Simplex Virus Reactivation in the Throat on Mechanical Ventilation with One or No Organ Failure

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Aciclovir
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Myasthenia gravis

Recruiting

Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

Registered drugNo placebo

Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

Registered drugNo placebo

France

Participants:0–17 years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Atypical haemolytic uraemic syndrome

Recruiting

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Iptacopan
Sponsor:Novartis Pharma AG

Contact Research Centre

Malignant peritoneal neoplasm+2

Recruiting

Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo

Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Aprepitant
Sponsor:K-Group Beta Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in St Germain En Laye

What the registry says about research in the country

01 Hematologic Oncology

Investigating innovative combination therapies for follicular lymphoma, comparing mosunetuzumab plus lenalidomide against standard treatments to improve progression-free survival in previously untreated patients.

Advanced lymphoma treatments
Targeted therapy combinations
Novel therapeutic approaches

Research focuses on enhancing treatment outcomes for high-risk lymphoma patients.

02 Breast Cancer Research

Evaluating treatment strategies for elderly women with HER2-negative breast cancer, examining the effectiveness of combined chemotherapy and hormone therapy based on genomic profiling.

Age-specific treatment protocols
Personalized therapy approaches
Genomic-guided interventions

Studies aim to optimize treatment outcomes for senior patients while considering their specific needs.

03 Neurological Disorders

Investigating treatment optimization for Secondary Progressive Multiple Sclerosis patients, focusing on the safety and efficacy of disease-modifying therapy withdrawal in stable patients over 50.

Treatment discontinuation studies
Age-specific MS management
Long-term disease monitoring

Research aims to enhance quality of life while maintaining disease stability.

04 Maternal Health

Examining preventive strategies for pregnancy-associated hypertension and pre-eclampsia through controlled trials of acetylsalicylic acid treatment in pregnant women with chronic hypertension.

Maternal-fetal outcomes
Preventive interventions
Pregnancy complications

Focus on reducing maternal and fetal morbidity through preventive care.

05 Endocrine Surgery

Investigating the effects of preoperative cholecalciferol supplementation on post-thyroidectomy outcomes, specifically focusing on preventing hypocalcemia complications.

Surgical outcome optimization
Preventive supplementation
Post-operative care

Research aims to improve patient recovery and reduce hospital stays after thyroid surgery.

Back to France All countries